医学
苯达莫司汀
养生
美罗华
内科学
中性粒细胞减少症
中止
肿瘤科
外科
淋巴瘤
化疗
作者
Prokop Vodička,Kateřina Benešová,Andrea Janíková,Vít Procházka,David Belada,Heidi Móciková,Kateřina Steinerová,Juraj Ďuraš,Josef Karban,Veronika Hanáčková,Alice Šýkorová,Aleš Obr,Marek Trněný
摘要
Polatuzumab vedotin with bendamustine and rituximab (Pola-BR) was approved for treatment of transplant-ineligible patients with relapsed/refractory DLBCL (R/R DLBCL). However, the number of patients treated in the GO29365 trial including the extension cohort was limited, and more data evaluating the efficacy of this treatment regimen is needed.We analyzed 21 patients with R/R DLBCL to determine real-life efficacy and safety of Pola-BR regimen. Data of all patients entered the database of the NiHiL project (NCT03199066).Median overall survival was 8.7 months, and progression-free survival 3.8 months. The overall response rate was 33%. Grade 3-4 neutropenia was detected in 29%, thrombocytopenia in 38%, anemia in 19%, infections in 24% cases, and peripheral neuropathy in 5%. Discontinuation of treatment was caused by progression in 50%, adverse events in 31%, and intended bridging to CAR-T therapy in 19%.Although the outcome of patients is worse than in GO29365 trial, the use of Pola-BR regimen in the real world demonstrates tolerable toxicity profile and efficacy in transplant-ineligible patients with R/R DLBCL. Moreover, this regimen might represent a perspective option as a bridge to CAR-T therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI